KR102658958B1 - 출혈의 치료 또는 예방에 사용하기 위한 혈액 응고 인자 대체품 - Google Patents

출혈의 치료 또는 예방에 사용하기 위한 혈액 응고 인자 대체품 Download PDF

Info

Publication number
KR102658958B1
KR102658958B1 KR1020197018871A KR20197018871A KR102658958B1 KR 102658958 B1 KR102658958 B1 KR 102658958B1 KR 1020197018871 A KR1020197018871 A KR 1020197018871A KR 20197018871 A KR20197018871 A KR 20197018871A KR 102658958 B1 KR102658958 B1 KR 102658958B1
Authority
KR
South Korea
Prior art keywords
treatment
factor
atiii
less
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197018871A
Other languages
English (en)
Korean (ko)
Other versions
KR20190111912A (ko
Inventor
에바 헤르조그
제랄드 호흐라이트너
올리버 그로트케
Original Assignee
체에스엘 베링 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 체에스엘 베링 게엠베하 filed Critical 체에스엘 베링 게엠베하
Publication of KR20190111912A publication Critical patent/KR20190111912A/ko
Application granted granted Critical
Publication of KR102658958B1 publication Critical patent/KR102658958B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21038—Coagulation factor XIIa (3.4.21.38)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020197018871A 2017-02-09 2018-02-09 출혈의 치료 또는 예방에 사용하기 위한 혈액 응고 인자 대체품 Active KR102658958B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17155420.7 2017-02-09
EP17155420 2017-02-09
PCT/EP2018/053240 WO2018146235A1 (en) 2017-02-09 2018-02-09 A blood coagulation factor replacement product for use in the treatment or prophyl of bleedings

Publications (2)

Publication Number Publication Date
KR20190111912A KR20190111912A (ko) 2019-10-02
KR102658958B1 true KR102658958B1 (ko) 2024-04-22

Family

ID=58016586

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197018871A Active KR102658958B1 (ko) 2017-02-09 2018-02-09 출혈의 치료 또는 예방에 사용하기 위한 혈액 응고 인자 대체품

Country Status (13)

Country Link
US (1) US11744880B2 (cg-RX-API-DMAC7.html)
EP (1) EP3579857B1 (cg-RX-API-DMAC7.html)
JP (1) JP7227905B2 (cg-RX-API-DMAC7.html)
KR (1) KR102658958B1 (cg-RX-API-DMAC7.html)
CN (1) CN110114074B (cg-RX-API-DMAC7.html)
AU (1) AU2018217375B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019012772A2 (cg-RX-API-DMAC7.html)
CA (1) CA3046406C (cg-RX-API-DMAC7.html)
DK (1) DK3579857T3 (cg-RX-API-DMAC7.html)
ES (1) ES2913934T3 (cg-RX-API-DMAC7.html)
PL (1) PL3579857T3 (cg-RX-API-DMAC7.html)
SG (1) SG10201912497WA (cg-RX-API-DMAC7.html)
WO (1) WO2018146235A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210308228A1 (en) * 2020-04-04 2021-10-07 The Board Of Regents Of The University Of Texas System Method for reducing the occurrence of thrombosis or thromboembolism
CN113929741A (zh) * 2020-06-29 2022-01-14 首都医科大学 华法林-4-O-乙酰-Gly-Pro-Arg-Pro-AA1及其合成、活性和应用
WO2026048976A1 (ja) * 2024-08-30 2026-03-05 Kmバイオロジクス株式会社 血液凝固第x因子を含む安定な医薬組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012528850A (ja) 2009-06-05 2012-11-15 ラボラトワール、フランセ、デュ、フラクショヌマン、エ、デ、ビオテクノロジ プロトロンビン複合体組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663164A (en) * 1980-01-28 1987-05-05 Baxter Travenol Laboratories, Inc. Aqueous compositions for treating blood clotting factor inhibitors
DE3101752A1 (de) 1981-01-21 1982-08-26 Behringwerke Ag, 3550 Marburg "verfahren zur reinigung der blutgerinnungsfaktoren ii, vii, ix und/oder x und danach hergestellte praeparationen"
DE3336631A1 (de) * 1983-10-08 1985-04-18 Behringwerke Ag, 3550 Marburg Verfahren zur pasteurisierung von plasma oder von konzentraten der blutgerinnungsfaktoren ii, vii, ix und x
DE3622642A1 (de) * 1986-07-05 1988-01-14 Behringwerke Ag Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung
SI0796623T1 (en) * 1996-03-20 2005-10-31 Baxter Aktiengesellschaft Pharmaceutical preparation for the treatment of blood coagulation disorders
AT409334B (de) 1997-09-19 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren
CN100415093C (zh) 2003-01-27 2008-09-03 哈维斯特技术公司 从抗凝全血生产的自体或同种促凝剂
DK2624859T3 (en) 2010-10-06 2017-06-06 Medimmune Ltd FACTOR II ALONE OR IN COMBINATION WITH OTHER FACTORS FOR TREATMENT OF REDUCED HEMOSTASE IN CONNECTION WITH DILUTION COAGULOPATHY
TWI653047B (zh) 2014-03-14 2019-03-11 百特製藥公司 用於在出血性病症的治療中促進止血的人類凝血酶原及活化因子x的組成物
WO2016198351A1 (en) * 2015-06-10 2016-12-15 Evonik Röhm Gmbh Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012528850A (ja) 2009-06-05 2012-11-15 ラボラトワール、フランセ、デュ、フラクショヌマン、エ、デ、ビオテクノロジ プロトロンビン複合体組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Grottke 등, Blood, 2011, 제118권 제7호 제1943~1951*

Also Published As

Publication number Publication date
WO2018146235A1 (en) 2018-08-16
CN110114074B (zh) 2024-05-28
CN110114074A (zh) 2019-08-09
CA3046406C (en) 2024-01-30
KR20190111912A (ko) 2019-10-02
US20190351028A1 (en) 2019-11-21
AU2018217375B2 (en) 2024-04-18
BR112019012772A2 (pt) 2019-12-10
AU2018217375A1 (en) 2019-06-27
ES2913934T3 (es) 2022-06-06
JP2020506880A (ja) 2020-03-05
WO2018146235A8 (en) 2019-05-09
CA3046406A1 (en) 2018-08-16
DK3579857T3 (da) 2022-06-07
SG10201912497WA (en) 2020-02-27
PL3579857T3 (pl) 2022-07-25
EP3579857B1 (en) 2022-04-06
JP7227905B2 (ja) 2023-02-22
EP3579857A1 (en) 2019-12-18
US11744880B2 (en) 2023-09-05

Similar Documents

Publication Publication Date Title
KR101567762B1 (ko) Fvⅲ 농축물을 포함하는 프로트롬빈 복합체 농축물의 상승적 치료 용도
US7767647B2 (en) Method of the invention preparations of factor IXa
US9968662B2 (en) Factor VII composition
JP2010006839A (ja) 組織因子経路インヒビター(tfpi)の低量投与による敗血症の処置
JP2017500372A (ja) 出血または凝固性低下と関係する容態の治療療法または予防療法
JP7227905B2 (ja) 出血の処置または予防における使用のための血液凝固因子代替製品
US20130244926A1 (en) Medicament for therapeutic treatment and/or improvement of sepsis
JP6000259B2 (ja) 止血障害治療用第ii因子およびフィブリノーゲン
Starczewska et al. Perioperative bleeding in patients undergoing liver transplantation
TWI441645B (zh) 作為新穎之局部用止血劑的活化型因子X(FXa)刺激劑
JP2004511428A (ja) 凝固亢進状態を処置するための製剤および方法
US20260014236A1 (en) Activators of coagulation factor x and formulations thereof for treating bleeding disorders
HK40017756B (en) A blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings
HK40017756A (en) A blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings
US12497607B2 (en) Plasminogen for use in treating and preventing lung dysfunction
US12514910B2 (en) Medicament for therapeutic treatment and/or improvement of sepsis accompanied by coagulopathy
WO2026048976A1 (ja) 血液凝固第x因子を含む安定な医薬組成物
JP2025522101A (ja) 止血を促進するための薬剤
JP2007055899A (ja) 血液凝固第x因子を主剤とする血液凝固異常に基づく疾患の治療・予防用医薬組成物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190628

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210202

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230725

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231114

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240207

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240416

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240417

End annual number: 3

Start annual number: 1

PG1601 Publication of registration